Cipher Pharmaceuticals has announced the Canadian launch of Brinavess (vernakalant hydrochloride) for the rapid conversion of recent onset atrial fibrillation (AF) to sinus rhythm (SR) for non-surgery patients with duration of AF less than seven days and post-cardiac surgery patients with duration of AF less than three days.
Johnson & Johnson (J&J) has agreed to acquire all outstanding shares of Japanese skincare firm, Ci:z Holdings, in a deal valued at around ¥230bn ($2.04bn).
Drug development services provider Quotient Sciences has opened a 45,000ft² manufacturing facility near Philadelphia, in Garnet Valley, Pennsylvania.
Dr. Reddy’s Laboratories has agreed to divest its its API manufacturing business unit located in Jeedimetla, Hyderabad, located in the Indian state of Telangana, to generics pharmaceutical firm Therapiva Private.
Clinical-stage firm eTheRNA immunotherapies has opened a mRNA facility in Belgium for production of mRNA immunotherapies.
Alliance Pharma has launched Xonvea, a new prescription drug for the treatment of nausea and vomiting of pregnancy (NVP), in the UK.
Dr. Reddy’s Laboratories has sold its antibiotic manufacturing facility and related assets in Bristol, Tennessee to Neopharma, a wholly owned subsidiary of the UAE’s largest pharmaceutical manufacturer headquartered in Abu Dhabi.
Recipharm has completed the purchase of Sanofi’s inhalation contract manufacturing business including a manufacturing plant situated in Holmes Chapel, UK.
Dova Pharmaceuticals, Salix Pharmaceuticals and its parent company Bausch Health Companies have entered into an exclusive agreement to co-promote Dova’s Doptelet (avatrombopag) in the US.
Gilead Sciences is planning to launch authorized generic versions of Epclusa (sofosbuvir 400mg/velpatasvir 100mg) and Harvoni (ledipasvir 90mg/sofosbuvir 400mg) in the US.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.